Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACRV Stock Forecast 2026-2027
$1.75
Current Price
$82.61M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ACRV Price Targets
+985.7%
To High Target of $19.00
+500.0%
To Median Target of $10.50
+300.0%
To Low Target of $7.00
ACRV Price Momentum
-10.7%
1 Week Change
+15.1%
1 Month Change
+32.6%
1 Year Change
-27.4%
Year-to-Date Change
-50.8%
From 52W High of $3.56
+45.8%
From 52W Low of $1.20
📊 TOP ANALYST CALLS
Did ACRV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Acrivon is one of their latest high-conviction picks.
Latest ACRV Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ACRV has a bullish consensus with a median price target of $10.50 (ranging from $7.00 to $19.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.75, the median forecast implies a 500.0% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACRV Analyst Ratings
8
Buy
0
Hold
0
Sell
ACRV Price Target Range
Low
$7.00
Average
$10.50
High
$19.00
Current: $1.75
Latest ACRV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACRV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $8.00 |
| Nov 25, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 14, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 16, 2025 | Jones Trading | Hold | Downgrade | $N/A | |
| May 15, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Mar 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 28, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Mar 26, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Mar 26, 2025 | Citizens Capital Markets | Market Outperform | Reiterates | $N/A | |
| Mar 26, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 31, 2025 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 14, 2024 | BMO Capital | Outperform | Maintains | $N/A | |
| Nov 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 14, 2024 | HC Wainwright& Co. | Buy | Reiterates | $N/A | |
| Sep 16, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Sep 16, 2024 | Ladenburg Thalmann | Buy | Upgrade | $N/A | |
| Sep 16, 2024 | BMO Capital | Outperform | Reiterates | $N/A | |
| Sep 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 15, 2024 | BMO Capital | Outperform | Reiterates | $N/A |
Acrivon Therapeutics, Inc. (ACRV) Competitors
The following stocks are similar to Acrivon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Acrivon Therapeutics, Inc. (ACRV) Financial Data
Acrivon Therapeutics, Inc. has a market capitalization of $82.61M with a P/E ratio of -1.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -60.4%.
Valuation Metrics
Market Cap
$82.61M
Enterprise Value
$-4,154,317
P/E Ratio
-1.0x
PEG Ratio
0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+130.5%
Current Ratio
9.0x
Debt/Equity
2.5x
ROE
-60.4%
ROA
-36.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Acrivon Therapeutics, Inc. (ACRV) Business Model
About Acrivon Therapeutics, Inc.
What They Do
Develops precision oncology medicines using proteomics.
Business Model
The company utilizes its proprietary generative phosphoproteomics platform to discover and develop targeted oncology therapies. It generates drug-specific OncoSignature companion diagnostics through its Acrivon Predictive Precision Proteomics (AP3) platform, which identifies patients likely to benefit from its drug candidates, thereby enhancing the effectiveness of cancer treatments and optimizing patient outcomes.
Additional Information
Acrivon's lead candidate, ACR-368, is currently in a registrational-intent Phase 2 study for endometrial cancer and exhibits activity in other cancer types. The company is based in Watertown, Massachusetts, and focuses on addressing unmet needs in cancer care through innovative drug discovery and precision medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
74
CEO
Dr. Peter Blume-Jensen M.D., Ph.D.
Country
United States
IPO Year
2022
Website
acrivon.comAcrivon Therapeutics, Inc. (ACRV) Latest News & Analysis
Latest News
Quick Summary
Acrivon Therapeutics (ACRV) is trading below its cash value. The AP3 platform shows a 50% response rate in endometrial cancer. Upcoming Phase 2b and Phase 1 data are key catalysts for growth.
Why It Matters
Acrivon Therapeutics (ACRV) is undervalued despite strong early data and potential catalysts, presenting an opportunity for upside as clinical results could enhance its market position.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Acrivon Therapeutics, Inc. (Nasdaq: ACRV), a clinical-stage biotech firm, utilizes its AP3 platform for drug design and development. CEO Peter Blume-Jensen announced recent company updates.
Why It Matters
Acrivon's leadership announcement could signal strategic shifts or new initiatives, impacting investor confidence and the company's future growth potential in precision medicine.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Acrivon Therapeutics (Nasdaq: ACRV) granted an equity award in stock options to an employee under its 2023 Inducement Plan on May 15, 2026.
Why It Matters
Acrivon's equity award signals potential growth and talent retention, indicating confidence in future developments. Such moves can impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
2 months ago
Quick Summary
The ACR-368 Phase 2b study for serous endometrial cancer is progressing, with an interim analysis and data update scheduled for the second half of 2026.
Why It Matters
The progress of the ACR-368 Phase 2b study, with an interim analysis set for 2026, may impact investor sentiment and stock performance based on potential treatment efficacy in endometrial cancer.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Preclinical trials show strong efficacy and lasting immune memory with ACR-368 or ACR-2316 combined with anti-PD-L1, and ACR-368 shows synergy with Topoisomerase 1 inhibition.
Why It Matters
The reported efficacy and synergy of ACR-368 and ACR-2316 in cancer treatments suggest potential for significant advancements in therapies, impacting market valuations and investment opportunities in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
3 months ago
Quick Summary
The Phase 2b ACR-368 study for serous endometrial cancer reports a confirmed overall response rate of 52%.
Why It Matters
A 52% confirmed overall response rate in a key Phase 2b study signals potential for a new treatment in serous endometrial cancer, likely impacting stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACRV Stock
What is Acrivon Therapeutics, Inc.'s (ACRV) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Acrivon Therapeutics, Inc. (ACRV) has a median price target of $10.50. The highest price target is $19.00 and the lowest is $7.00.
Is ACRV stock a good investment in 2027?
According to current analyst ratings, ACRV has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACRV stock?
Wall Street analysts predict ACRV stock could reach $10.50 in the next 12 months. This represents a 500.0% increase from the current price of $1.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Acrivon Therapeutics, Inc.'s business model?
The company utilizes its proprietary generative phosphoproteomics platform to discover and develop targeted oncology therapies. It generates drug-specific OncoSignature companion diagnostics through its Acrivon Predictive Precision Proteomics (AP3) platform, which identifies patients likely to benefit from its drug candidates, thereby enhancing the effectiveness of cancer treatments and optimizing patient outcomes.
What is the highest forecasted price for ACRV Acrivon Therapeutics, Inc.?
The highest price target for ACRV is $19.00 from at , which represents a 985.7% increase from the current price of $1.75.
What is the lowest forecasted price for ACRV Acrivon Therapeutics, Inc.?
The lowest price target for ACRV is $7.00 from at , which represents a 300.0% increase from the current price of $1.75.
What is the overall ACRV consensus from analysts for Acrivon Therapeutics, Inc.?
The overall analyst consensus for ACRV is bullish. Out of 2 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.50.
How accurate are ACRV stock price projections?
Stock price projections, including those for Acrivon Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:02 AM UTC